XXXX , 4, and 15 expression in solid tumors of lung adenocarcinoma versus @entity3620 .

@entity1 @entity21487 @entity72040 @entity5 @entity189 @entity2615 @entity420 @entity3620 @entity17290 @entity14187 @entity2220 @entity7457
UNASSIGNED: Epithelioid @entity3620 ( @entity3620 ) can easily be confused with @entity2220 ( @entity420 ). In serous effusion, @entity14187 is shown to be useful in the diagnosis of @entity2615 vs @entity420 . @entity72040 is reported to be overexpressed in epithelioid @entity2615 and absent in @entity1 airway epithelium. The aim was to assess the value of @entity14187 and @entity17290 compared to that of BerEp4 and @entity7457 ( @entity7457 ) in differentiating lung ACA from epithelioid @entity3620 and to examine the expression of @entity72040 in these @entity5 . The expression of @entity14187 , @entity17290 , @entity72040 , BerEp4, and @entity7457 was examined by immunohistochemistry in a total of 62 @entity1 specimen including 28 epithelioid MPMs and 34 @entity420 of the lung. In lung ACA, @entity17290 was strongly expressed in all 34 (100%) specimens followed by @entity14187 in 33 (97%) of 34. BerEp4 was expressed in 32 (94.1%) of 34. @entity7457 reacted for only 20 (58.82%) of 34 cases of lung ACA. In @entity3620 specimens, the expression of @entity21487 as well as that of @entity7457 was completely absent. In contrast, BerEp4 was focally expressed in 5 (17.85%) of 28 cases of epithelioid @entity3620 . @entity72040 was strongly expressed in 53% pf epithelioid MPMs but also in 50% of lung @entity420 . Its expression was moderate in normal pleura and limited in normal lung. @entity14187 and @entity17290 appear to be the best performing @entity189 markers in discriminating lung ACA from @entity2615 compared with BerEp4 and @entity7457 . There is no differential expression of @entity72040 between the 2 pathologies. However, the limited @entity72040 expression in normal tissues and high expression in @entity5 make it an attractive candidate for @entity5 therapy.
